At ZyVersa Therapeutics' 2024 Annual Meeting held on October 29, stockholders approved several key proposals with approximately 43% of shares represented. Shareholders elected Min Chul Park, Ph.D. as Class II director and ratified Marcum LLP as the independent auditor for 2024.Notably, stockholders approved the amendment of the 2022 Omnibus Equity Incentive Plan, increasing the share reserve by 150,000 to 181,795 shares. Additionally, they authorized the issuance of up to 478,600 common shares upon exercise of certain warrants, in compliance with Nasdaq Listing Rule 5635(d).The meeting saw strong shareholder support across all proposals, with the auditor ratification receiving the highest approval at 433,670 votes in favor. The equity plan amendment passed with 166,445 supporting votes, while the warrant issuance proposal secured 163,788 favorable votes.

At ZyVersa Therapeutics' 2024 Annual Meeting held on October 29, stockholders approved several key proposals with approximately 43% of shares represented. Shareholders elected Min Chul Park, Ph.D. as Class II director and ratified Marcum LLP as the independent auditor for 2024.Notably, stockholders approved the amendment of the 2022 Omnibus Equity Incentive Plan, increasing the share reserve by 150,000 to 181,795 shares. Additionally, they authorized the issuance of up to 478,600 common shares upon exercise of certain warrants, in compliance with Nasdaq Listing Rule 5635(d).The meeting saw strong shareholder support across all proposals, with the auditor ratification receiving the highest approval at 433,670 votes in favor. The equity plan amendment passed with 166,445 supporting votes, while the warrant issuance proposal secured 163,788 favorable votes.